Edition:
United States

People: Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

4.10USD
22 Sep 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$4.10
Open
$4.07
Day's High
$4.13
Day's Low
$4.04
Volume
330,634
Avg. Vol
1,013,960
52-wk High
$7.49
52-wk Low
$3.20

Sharp, Shalini 

Ms. Shalini Sharp is an Independent Director of the Company. Ms. Sharp is Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc. (“Ultragenyx”). She originally joined Ultragenyx in May 2012 as its Chief Financial Officer. Ms. Sharp served as Chief Financial Officer of Agenus from 2006 to May 2012, and was appointed a member of the Board in May 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development activities. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company’s restructuring. Prior to Elan, Ms. Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp currently serves on the Board of Array BioPharma Inc. (NASDAQ: ARRY) and is also a member of the Board of the TB Alliance. Ms. Sharp holds both a bachelor’s degree and a master’s degree in business administration from Harvard University. Ms. Sharp brings to our Board over a decade of institutional knowledge of Agenus as well as her expertise in biotechnology, corporate strategy, and finance.

Basic Compensation

Total Annual Compensation, USD 128,061
Restricted Stock Awards, USD 114,873
Long-Term Incentive Plans, USD --
All Other, USD 7,185
Fiscal Year Total, USD 250,119

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --